

Abstract:

Proclara Biosciences Inc. (formerly NeuroPhage) focuses on the development of highly differentiated drug candidates that simultaneously target multiple toxic misfolded proteins. Company was founded on groundbreaking work from prof. Beka Solomon at Tel Aviv University, demonstrating that a filamentous bacteriophage can remodel different types of misfolded proteins associated with neuro degenerative disease.

Further work elucidated the mechanism of action and its lead candidates, NPT088, is a fusion protein with a fragment of the bacteriophage.

The company to date raised north of \$110M, boasts a world class team and its lead candidates NPT088 is in early claim trial in Alzheimer's patients.

Jonathan Solomon
ProClara / NeuroPhage